This partnership combines global expertise with regional leadership in precision oncology to enhance education, drive innovation, and improve patient access.
February 27, 2026 – Wiesbaden, Germany and Miami, USA. The International Centers for Precision Oncology (ICPO) Foundation and the UroTeragLATAM Foundation have inked a Memorandum of Understanding during the WFNMB congress in Cartagena, Colombia. Their collaboration aims to advance Theranostics education via the ICPO Academy for Theranostics, promote research, and improve patient access to Theranostics for urological cancer across Latin America. By integrating ICPO’s global Theranostics expertise with UroTeragLATAM’s regional leadership in education and multidisciplinary cooperation in this field, the partnership intends to expedite the adoption of precision oncology. Together, the two foundations will encourage innovation, boost knowledge exchange, and support the development of Theranostics centers throughout the region.
Theranostics – a fast – evolving approach that fuses diagnostic imaging with targeted therapy using radiopharmaceuticals – marks a significant change in cancer treatment. Established in 2019, the ICPO Foundation is committed to increasing global patient access to Theranostics through its accredited ICPO Theranostics Centers Network, educational programs, support for ICPO Research Grants, and international community – building activities. The UroTeragLATAM Foundation, founded in 2025, is focused on promoting education and collaboration in Theranostics for urological cancers across Latin America, with the goal of becoming the top genitourinary Theranostics education platform in the region.
“Latin America is emerging as a vibrant force in Theranostics, and partnerships like the one with UroTeragLATAM are crucial for unleashing its full potential. By joining hands with a regional cancer – specific foundation, ICPO is not only connecting global expertise but also jointly creating sustainable paths for innovation, clinical excellence, and long – term impact in precision oncology to achieve better patient outcomes,” stressed Odile Jaume, CEO of the ICPO Foundation.
“This partnership is more than just accelerating Theranostics in Latin America; it sets a new standard for global cooperation. By bringing together strong regional leadership and a truly cross – border alliance, ICPO and UroTeragLATAM are creating a model that can inspire and guide other regions looking to expand access to precision oncology,” said Dr. Danny Mena Cortes, President of UroTeragLATAM.
Strengthening Education and Clinical Excellence
UroTeragLATAM will promote the ICPO Academy of Theranostics, providing complimentary access for academic participants based on ICPO stipend criteria and availability. Both organizations will work together to support the expansion of the ICPO Academy in Latin American countries. This is possible due to the involvement of Latin American multidisciplinary experts in jointly creating new relevant educational resources, facilitating local certifications, and identifying valuable opportunities for practical training.
Building a Stronger Theranostics Ecosystem
The MoU details joint efforts to enhance the Theranostics capacity and infrastructure across the Latin American region. UroTeragLATAM will put forward new candidates for ICPO Theranostics Centers and encourage them to apply for the ICPO Clinical Centers of Excellence accreditation. ICPO and UroTeragLATAM will also collaborate on scientific projects and advocacy work to ensure that patients at regional and local levels can access innovative cancer care solutions.
Supporting Innovation and Research
The agreement also creates a framework for scientific collaboration. UroTeragLATAM will encourage research participation and promote grant applications from the Latin American region, while ICPO will evaluate proposals through its established scientific review processes. Together, the foundations aim to cultivate emerging talent and advance Theranostics on a global scale.
Photo caption:
Juan Davila, Partner Engagement & Fundraising Director, Dr. Marwa Hakkam, Accreditation and Center Director, (both ICPO Foundation) and Julian Rojas, Board Member UroTeragLATAM, Colombia (f.l.t.r.)
About ICPO Foundation
The International Centers for Precision Oncology Foundation (ICPO) is a non – profit organization established in 2019 under German law by leading international medical practitioners and life sciences entrepreneurs. Recognizing the shift in cancer care towards a personalized approach, the ICPO Foundation is helping to build momentum to increase global patient access. It does this by developing an international network of physical diagnostic and therapeutic centers for Precision Oncology based on a model of shared knowledge, certified education through the ICPO Academy for Theranostics, and standardization of design and processes to enable the best clinical practices for better patient outcomes worldwide. Learn more about the ICPO Foundation www.icpo.foundation and the ICPO Academy for Theranostics
Media contact ICPO Foundation
Susanne Simon, Head of Communication & Community
Email: , Phone: + 49 172 8666093,
About UroTeragLATAM Foundation
The main activities of the UroTeragLATAM Foundation involve organizing and hosting educational events such as conferences, workshops, and symposia. These events are meticulously designed to offer participants the latest and most up – to – date information in Spanish on radiopharmaceutical therapies for genitourinary (GU) oncological pathologies, with an emphasis on their practical application in clinical settings in Latin America. The organization also promotes professional cooperation by creating networking opportunities, discussion forums, and platforms where healthcare professionals can share experiences, knowledge, and best practices. Additionally, UroTeragLATAM supports continuing medical education by providing access to online learning modules, research resources, and educational materials to ensure that healthcare providers stay informed about the latest developments in Theranostics. UroTeragLATAM also creates in – person spaces to discuss new evidence in GU theragnosis through collaborations with other academic activities, associations in urology, oncology, nuclear medicine, and medical physics, and by organizing symposia within congresses.
Media Contact UroTeragLATAM Foundation
Dr. Andrea Luna Mass
Email:
Website: uroteraglatam.com
Attachments
